The HIVconsv Vaccines Induce Polyfunctional and Highly Proliferative T Cells that Control In Vitro HIV Replication: HIV-CORE002 Phase-I Clinical Trial

The HIVconsv Vaccines Induce Polyfunctional and Highly Proliferative T Cells that Control In Vitro HIV Replication: HIV-CORE002 Phase-I Clinical Trial

Bibliographic Details
Main Authors:	Ondondo, B, Ahmed, T, Nicola, B, Hayton, E, Vasilyeva, E, Frahm, N, Colloca, S, Nicosia, A, McMichael, A, Dorrell, L, Hanke, T
Format:	Conference item
Published:	2013

Similar Items

Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: One Year Follow On and Epitope Mapping
by: Borthwick, N, et al.
Published: (2013)

Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice.
by: Ondondo, B, et al.
Published: (2013)

Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice
by: Ondondo, B, et al.
Published: (2013)

Targeting HIV-1 Where It Hurts
by: Ahmed, T, et al.
Published: (2013)

Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects
by: Hancock, G, et al.
Published: (2017)

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1
by: Borthwick, N, et al.
Published: (2014)

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.
by: Borthwick, N, et al.
Published: (2014)

Optimizing Delivery of the HIVconsv Immunogen in Rhesus Macaques
by: Rosario, M, et al.
Published: (2011)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
by: Borthwick, N, et al.
Published: (2012)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
by: Borthwick NJ, et al.
Published: (2012-09-01)

Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: Mapping of CD8+ T Cell Epitopes.
by: Borthwick, N, et al.
Published: (2014)

IL-10 Receptor Blockade Enhances CD4 and CD8 T Cell Responses to a Simian Adenovirus-Vectored HIV-1 Vaccine, ChAdV63.HIVconsv
by: Clutton, G, et al.
Published: (2013)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and ChAdV-63 in a phase I/IIa clinical trial
by: Hanke, T, et al.
Published: (2012)

Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques.
by: Rosario, M, et al.
Published: (2010)

Targeting HIV-1 where it hurts
by: Borthwick, N, et al.
Published: (2013)

pTHr.HIVA and MVA.HIVA vaccines (gag p24/p17) augment CD4+T cell responses in chronically infected HIV-1 patients on HAART
by: Ondondo, B, et al.
Published: (2005)

Polyfunctional T cell responses are a hallmark of HIV-2 infection.
by: Duvall, MG, et al.
Published: (2008)

Humoral responses to HIVconsv induced by heterologous vaccine modalities in rhesus macaques
by: Borthwick, N, et al.
Published: (2015)

Parallel induction of CH505 B cell ontogeny-guided neutralizing antibodies and tHIVconsvX conserved mosaic-specific T cells against HIV-1
by: Wee, E, et al.
Published: (2019)

The 2nd generation of a T-cell vaccine against HIV based on conserved region mosaics
by: Ondondo, B, et al.
Published: (2014)

HIVconsv vaccines and romidepsin in early-treated HIV-1-infected individuals: Safety, immunogenicity and effect on the viral reservoir (Study BCN02)
by: Mothe, B, et al.
Published: (2020)

HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)
by: Beatriz Mothe, et al.
Published: (2020-05-01)

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1
by: Ahmed, T, et al.
Published: (2012)

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1
by: Ahmed T, et al.
Published: (2012-09-01)

Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses.
by: Ondondo, B, et al.
Published: (2006)

Aiming for protective T-cell responses: A focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials
by: Hanke, T
Published: (2019)

Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1
by: Edmund G. Wee, et al.
Published: (2022-06-01)

PedVACC 001 and 002: building foundations for infant HIV-1 vaccine trials against breast milk transmission of HIV-1
by: Hanke, T
Published: (2012)

The immune response to HIV
by: McMichael, A, et al.
Published: (2009)

Adenovirus Transcriptome in Human Cells Infected with ChAdOx1-Vectored Candidate HIV-1 Vaccine Is Dominated by High Levels of Correctly Spliced HIVconsv1&62 Transgene RNA
by: David A. Matthews, et al.
Published: (2023-07-01)

Dealing with HIV-I diversity
by: Rosario, M, et al.
Published: (2009)

Comprehensive analysis of HIV Gag-specific IFN-gamma response in HIV-1- and HIV-2-infected asymptomatic patients from a clinical cohort in The Gambia.
by: Ondondo, B, et al.
Published: (2008)

Polyfunctionality and breadth of HIV-1 antibodies are associated with delayed disease progression.
by: Marloes Grobben, et al.
Published: (2024-12-01)

Detection of broad functional gag-specific CD4+T cell responses in HIV-1-infected subjects following therapeutic immunization with rMVA expressing an HIV-1 gag immunogen
by: Ondondo, B, et al.
Published: (2006)

Characterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB/c mice.
by: Ondondo, B, et al.
Published: (2014)

Is an HIV vaccine possible?
by: Mcmichael, A, et al.
Published: (1999)

Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay.
by: Winstone, N, et al.
Published: (2009)

HIV vaccines 1983-2003.
by: Mcmichael, A, et al.
Published: (2003)

P17-05. Dealing with HIV-1 diversity
by: Rosario, M, et al.
Published: (2009)

Characterisation of T cells induced by candidate prophylactic vaccines encoding a HIV-1 conserved immunogen in phase I/IIa trial HIVCORE002
by: Ahmed, T, et al.
Published: (2011)